Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.92
BSPM's Cash to Debt is ranked lower than
63% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. BSPM: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
BSPM' s 10-Year Cash to Debt Range
Min: 0.54  Med: 9999.00 Max: No Debt
Current: 0.92
Equity to Asset 0.90
BSPM's Equity to Asset is ranked higher than
92% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BSPM: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
BSPM' s 10-Year Equity to Asset Range
Min: 0.79  Med: 0.88 Max: 0.96
Current: 0.9
0.79
0.96
F-Score: 4
Z-Score: 2.73
M-Score: -2.09
WACC vs ROIC
29.20%
7.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -2.61
BSPM's Operating margin (%) is ranked lower than
76% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. BSPM: -2.61 )
Ranked among companies with meaningful Operating margin (%) only.
BSPM' s 10-Year Operating margin (%) Range
Min: -44.17  Med: 21.32 Max: 30.5
Current: -2.61
-44.17
30.5
Net-margin (%) 7.94
BSPM's Net-margin (%) is ranked higher than
58% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. BSPM: 7.94 )
Ranked among companies with meaningful Net-margin (%) only.
BSPM' s 10-Year Net-margin (%) Range
Min: -40.55  Med: 16.47 Max: 24.95
Current: 7.94
-40.55
24.95
ROE (%) 6.31
BSPM's ROE (%) is ranked higher than
51% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. BSPM: 6.31 )
Ranked among companies with meaningful ROE (%) only.
BSPM' s 10-Year ROE (%) Range
Min: -29.81  Med: 17.78 Max: 34.28
Current: 6.31
-29.81
34.28
ROA (%) 5.61
BSPM's ROA (%) is ranked higher than
61% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BSPM: 5.61 )
Ranked among companies with meaningful ROA (%) only.
BSPM' s 10-Year ROA (%) Range
Min: -26.05  Med: 16.11 Max: 30.2
Current: 5.61
-26.05
30.2
ROC (Joel Greenblatt) (%) 1.24
BSPM's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. BSPM: 1.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSPM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -57.11  Med: 50.12 Max: 126.97
Current: 1.24
-57.11
126.97
Revenue Growth (3Y)(%) -24.60
BSPM's Revenue Growth (3Y)(%) is ranked lower than
93% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BSPM: -24.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSPM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -24.6  Med: -7.80 Max: 56.6
Current: -24.6
-24.6
56.6
EBITDA Growth (3Y)(%) -45.50
BSPM's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. BSPM: -45.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BSPM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.5  Med: -9.45 Max: 50
Current: -45.5
-45.5
50
EPS Growth (3Y)(%) -36.80
BSPM's EPS Growth (3Y)(%) is ranked lower than
87% of the 451 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BSPM: -36.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BSPM' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.7  Med: -5.90 Max: 49.4
Current: -36.8
-66.7
49.4
» BSPM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BSPM Guru Trades in Q2 2014

Jim Simons 563,670 sh (+4.18%)
» More
Q3 2014

BSPM Guru Trades in Q3 2014

Jim Simons 594,670 sh (+5.50%)
» More
Q4 2014

BSPM Guru Trades in Q4 2014

Jim Simons 603,470 sh (+1.48%)
» More
Q1 2015

BSPM Guru Trades in Q1 2015

Jim Simons 632,870 sh (+4.87%)
» More
» Details

Insider Trades

Latest Guru Trades with BSPM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2.56
BSPM's P/E(ttm) is ranked higher than
98% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.90 vs. BSPM: 2.56 )
Ranked among companies with meaningful P/E(ttm) only.
BSPM' s 10-Year P/E(ttm) Range
Min: 1.03  Med: 4.87 Max: 78.16
Current: 2.56
1.03
78.16
PE(NRI) 3.20
BSPM's PE(NRI) is ranked higher than
98% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.00 vs. BSPM: 3.20 )
Ranked among companies with meaningful PE(NRI) only.
BSPM' s 10-Year PE(NRI) Range
Min: 1.03  Med: 4.83 Max: 74.25
Current: 3.2
1.03
74.25
P/B 0.15
BSPM's P/B is ranked higher than
99% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. BSPM: 0.15 )
Ranked among companies with meaningful P/B only.
BSPM' s 10-Year P/B Range
Min: 0.11  Med: 0.32 Max: 3.04
Current: 0.15
0.11
3.04
P/S 0.22
BSPM's P/S is ranked higher than
96% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. BSPM: 0.22 )
Ranked among companies with meaningful P/S only.
BSPM' s 10-Year P/S Range
Min: 0.13  Med: 0.32 Max: 2.2
Current: 0.22
0.13
2.2
POCF 3.92
BSPM's POCF is ranked higher than
94% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.86 vs. BSPM: 3.92 )
Ranked among companies with meaningful POCF only.
BSPM' s 10-Year POCF Range
Min: 0.51  Med: 3.87 Max: 20.4
Current: 3.92
0.51
20.4
EV-to-EBIT 23.30
BSPM's EV-to-EBIT is ranked lower than
54% of the 486 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.52 vs. BSPM: 23.30 )
Ranked among companies with meaningful EV-to-EBIT only.
BSPM' s 10-Year EV-to-EBIT Range
Min: -77.1  Med: 0.50 Max: 87.8
Current: 23.3
-77.1
87.8
Shiller P/E 1.78
BSPM's Shiller P/E is ranked higher than
98% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.83 vs. BSPM: 1.78 )
Ranked among companies with meaningful Shiller P/E only.
BSPM' s 10-Year Shiller P/E Range
Min: 1.13  Med: 2.90 Max: 6.06
Current: 1.78
1.13
6.06
Current Ratio 5.02
BSPM's Current Ratio is ranked higher than
79% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. BSPM: 5.02 )
Ranked among companies with meaningful Current Ratio only.
BSPM' s 10-Year Current Ratio Range
Min: 1.68  Med: 5.28 Max: 19.49
Current: 5.02
1.68
19.49
Quick Ratio 4.97
BSPM's Quick Ratio is ranked higher than
81% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. BSPM: 4.97 )
Ranked among companies with meaningful Quick Ratio only.
BSPM' s 10-Year Quick Ratio Range
Min: 1.63  Med: 5.12 Max: 19.17
Current: 4.97
1.63
19.17
Days Inventory 8.22
BSPM's Days Inventory is ranked higher than
97% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. BSPM: 8.22 )
Ranked among companies with meaningful Days Inventory only.
BSPM' s 10-Year Days Inventory Range
Min: 6.29  Med: 8.81 Max: 20.81
Current: 8.22
6.29
20.81
Days Sales Outstanding 162.94
BSPM's Days Sales Outstanding is ranked lower than
89% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.86 vs. BSPM: 162.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSPM' s 10-Year Days Sales Outstanding Range
Min: 94.72  Med: 132.71 Max: 161.72
Current: 162.94
94.72
161.72

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 0.37
BSPM's Price/Net Current Asset Value is ranked higher than
99% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.66 vs. BSPM: 0.37 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BSPM' s 10-Year Price/Net Current Asset Value Range
Min: 0.26  Med: 0.57 Max: 4.31
Current: 0.37
0.26
4.31
Price/Tangible Book 0.21
BSPM's Price/Tangible Book is ranked higher than
99% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. BSPM: 0.21 )
Ranked among companies with meaningful Price/Tangible Book only.
BSPM' s 10-Year Price/Tangible Book Range
Min: 0.19  Med: 0.40 Max: 3.49
Current: 0.21
0.19
3.49
Price/Projected FCF 0.14
BSPM's Price/Projected FCF is ranked higher than
99% of the 321 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. BSPM: 0.14 )
Ranked among companies with meaningful Price/Projected FCF only.
BSPM' s 10-Year Price/Projected FCF Range
Min: 0.1  Med: 0.22 Max: 0.36
Current: 0.14
0.1
0.36
Price/Median PS Value 0.68
BSPM's Price/Median PS Value is ranked higher than
86% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. BSPM: 0.68 )
Ranked among companies with meaningful Price/Median PS Value only.
BSPM' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 1.03 Max: 6.36
Current: 0.68
0.43
6.36
Price/Graham Number 0.16
BSPM's Price/Graham Number is ranked higher than
99% of the 366 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. BSPM: 0.16 )
Ranked among companies with meaningful Price/Graham Number only.
BSPM' s 10-Year Price/Graham Number Range
Min: 0.12  Med: 0.43 Max: 1.24
Current: 0.16
0.12
1.24
Earnings Yield (Greenblatt) (%) 4.24
BSPM's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. BSPM: 4.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSPM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 33.95 Max: 7626.1
Current: 4.24
1.1
7626.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:7BNA.Germany,
Biostar Pharmaceuticals Inc is a Maryland corporation incorporated on March 27, 2007. It is a holding company that through its wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. and its variable interest entities Shaanxi Aoxing Pharmaceutical Co., Ltd., and Shaanxi Weinan Aoxing Pharmaceuticals, LLC develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the Peoples Republic of China. Its popular product is Xin Ao Xing Oleanolic Acid Capsule, an over-the- counter (OTC) medicine for chronic hepatitis B. Its product line also includes five other OTC products, ten prescription-based pharmaceuticals, six nutriceuticals or health products and one medical device. The Company's products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. It has currently eight products under development to complement its existing product line. It has adopted international manufacturing standards and currently holds one patent, with two additional patents pending approval. The Company's products are currently being sold in over 25 provinces in the PRC through 25 distributors and an established network of more than 400 dedicated sales people. The Company's competitors includes, Wulanhaote Zhong Meng pharmaceutical Co., Ltd., Yang Ling Mai Di Sen Pharmaceutical Co., Ltd, Jiang Xi Ren He Pharmaceuticals, Inc; Hainan Asia Pharmaceuticals, Inc; Nan Yong An Pharmaceuticals, Inc; Hai Nan Min Hai Pharmaceuticals, Ltd; Shandong Bai Cao Pharmaceuticals, Ltd; Chang Chun Ren Min Pharmaceuticals, Ltd; Yun Nan Yu Xi City Wei He Pharmaceutical, Ltd; Shandong Phoenix Pharmaceuticals, Ltd; Wulanhaote Zhong Meng Pharmaceutical Co., Ltd; Yang Ling Mai Di Sen Pharmaceutical Co., Ltd; and other traditional Chinese medicine suppliers. The Company' operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protection bureaus in the PRC.
» More Articles for BSPM

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: ANADIGICS Inc., Biostar Pharmaceuticals Inc., Astrotech Corp. May 30 2011 

More From Other Websites
BIOSTAR PHARMACEUTICALS, INC. Financials May 27 2015
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 15 2015
Biostar Pharmaceuticals,Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2015 May 15 2015
Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results May 04 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Apr 15 2015
Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results Apr 15 2015
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Apr 15 2015
Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with... Jan 08 2015
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Dec 05 2014
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results Nov 15 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results Nov 14 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Oct 23 2014
Biostar Pharmaceuticals, Inc. Files a PRC Patent Application for Oleanolic Acid Injection, its New... Sep 18 2014
Biostar Pharmaceuticals Inc. Engaged Chief Scientist Professor Xiaohui Zheng To Preside Over The... Aug 27 2014
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China Aug 18 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results Aug 14 2014
Biostar Pharmaceuticals Inc. Established a Sales and Marketing Task Team to Promote Sales to... Aug 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK